Jonathan Zenilman, MD

COU Co-Director
Jonathan Zenilman, MD

Contact Information


Dr. Zenilman has extensive experience in leadership clinical epidemiology and clinical trials, including sexually transmitted infections, Phase 2-3 trials of antimicrobials and diagnostics in outpatient and inpatient settings, and first-in-human Phase 1 trials conducted under controlled conditions which assessed toxicity and pharmacokinetics. His clinical trial work has been supported by NIAID, CDC, and commercial sponsors, and he has been a principal investigator and has managed sites in the STD Clinical Trials Group, HPTN, the Baltimore City Health Department STD program and the JHU Institute for Clinical and Translational Research. He has served on numerous NOH and CDC advisory committees and has participated in every revision of the STD Treatment Guidelines since 1989.  He was previously site PI for the NIAID/DMID funded Phase I clinical studies program that was one of the predecessors for this application and has extensive familiarity experience with DMID processes for quality assurance, site SOPs, FDA IND submissions, and protocol operationalization.  Since 2013, he has been a member of the Johns Hopkins IRB, and has substantial experience in human subjects’ issues, ethics and clinical research regulation, and served as a technical expert for the Presidential Commission on Bioethical Issues which investigated the USPHS Guatemala studies.